Africa: Unitaid Invests U.S.$22m to Accelerate Access to Lenacapavir, a Groundbreaking New HIV Prevention Drug

[UNITAID] Geneva — Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to lenacapavir, a revolutionary long-acting HIV prevention option. Two injections of lenacapavir per year, under the skin, provide effective protection against HIV. Unitaid’s US$22 million investment builds on our ongoing efforts to expand supply and demand for long-acting pre-exposure prophylaxis (PrEP) products used to prevent HIV infection, ensuring this transformative innovation reaches



Source link : https://allafrica.com/stories/202411290024.html

Author :

Publish date : 2024-11-29 05:08:30

Copyright for syndicated content belongs to the linked Source.